• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Credit agencies lower Medtronic’s rating post-Covidien merger

Credit agencies lower Medtronic’s rating post-Covidien merger

January 28, 2015 By Brad Perriello

Credit agencies lower Medtronic's rating post-Covidien merger

Credit agencies this week kept their promises to downgrade their ratings on Medtronic‘s (NYSE:MDT) debt now that its blockbuster $50 billion acquisition of Covidien is a done deal.

Standard & Poor’s Ratings Services, Moody’s Investors Service and Fitch Ratings all either demoted Medtronic’s debt or the Covidien debt it assumed in the deal – although, interestingly, Moody’s did raise its rating on Covidien’s debt.

Moody’s said the merger prompted it to downgrade Medtronic’s senior unsecured ratings to A3 from A2 and its short-term rating to Prime-2 from Prime-1, lowering its rating outlook to negative. But Moody’s also said it’s upgrading Covidien’s senior unsecured debt rating to A3 from Baa1. The $50 billion deal closed Jan. 26.

"The upgrade is supported by Moody’s opinion that Covidien’s existing bondholders are moderately better off because they now receive downstream guarantees from A3-rated Medtronic, but will not be required to provide upstream guarantees," according to a press release. "However, Moody’s is not making a rating distinction between any of the debt in Medtronic’s capital structure because of the solid credit strength of the combined entity, the very low probability of default, and the downstream guarantees from entities at or near the top of the corporate structure. Existing debt issued by Covidien – along with all other Medtronic debt – will have downstream guarantees from Medtronic plc, the new parent entity, which will be domiciled in Ireland, and from Medtronic Global Holdings SCA, which is the new post-close borrowing entity."

Standard & Poor’s cut its rating on Medtronic from A to AA- and put a stable outlook on the debt. But S&P also lowered its commercial paper rating to A-1 from A-1+.

"The downgrade reflects our view that the incremental strengthening of the business risk from the acquisition of Covidien is more than offset by the considerable increase in debt leverage," Standard & Poor’s credit analyst David Kaplan said in prepared remarks.

Fitch said it downgraded Covidien’s issuer default rating to A- from A and assigned a negative rating outlook to the debt.

Filed Under: Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: Covidien, Fitch Ratings, Medtronic buys Covidien, Moody's Investor Service, Standard & Poor's

More recent news

  • GI Windows wins FDA nod for magnet tech
  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy